GlassScriptPhysician profile
Fernanda Amaral Cooley
NPI 1235656216
$15,516.01
in general payments reported to CMS, 2019-2025
19 companies · $5,058 in 2025
The $5,058 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
See the full distribution for Psychiatric/Mental Health (Registered Nurse)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,265 · 2022: $1,740 · 2023: $3,210 · 2024: $4,243 · 2025: $5,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,288.11 |
| Education | $222.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,807.22 | 2021-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $1,960.57 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $1,816.06 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,247.94 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,165.46 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,104.04 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $1,092.53 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $1,087.87 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,000.63 | 2021-2025 | Caplyta |
| Indivior INC. | $753.27 | 2023-2025 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $562.24 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $248.59 | 2023-2024 | Qelbree, Qelbree |
| Pear Therapeutics (US), INC. | $167.27 | 2022 | |
| Lundbeck LLC | $131.27 | 2024-2025 | Rexulti |
| Corium, LLC | $123.28 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $115.16 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $53.15 | 2023 | Secuado, Xelstrym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $47.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernanda Cooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.